Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Natera Inc. Common Stock — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $63.6 (market cap $79.86B), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is the larger of the two by market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.32% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 108 Days and Natera Inc. Common Stock for 0 Days on average.
| MDLZ | NTRA | |
|---|---|---|
Market Cap | $79.86B | $57.03B |
Volume | 7,299,804 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $425.64 |
52-Week Low | $51.51 | $179.42 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | $100.20B | $56.18B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $61.50, down 0.47% on the day, with strong technical momentum indicated by bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth continues with $38.54 billion in 2025, though net income margin declined to 6.36% from 12.65% in 2024. Analyst consensus remains strongly bullish with a $70.29 price target, representing 14% upside potential.
MDLZ offers attractive valuation with a P/E of 22.53 and consistent dividend growth, recently raising its quarterly payout to $0.52. Key risks include cocoa cost pressures and margin compression, but the company's global brand strength and emerging market momentum provide stability. The stock presents a compelling opportunity for long-term investors seeking defensive exposure with dividend income.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
